

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, ZRG1 SBIB R 15B: Small Business: Ultrasound.

*Date:* October 19, 2004.

*Time:* 1:30 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Hector Lopez, DSC, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5120, MSC 7854, Bethesda, MD 20892, (301) 435-2392, [lopezh@csr.nih.gov](mailto:lopezh@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Program Project in Cell Biology.

*Date:* October 21–22, 2004.

*Time:* 6 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The River Inn, 924 25th Street, NW., Washington, DC 20037.

*Contact Person:* Alexandra M. Ainsztein, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5144, MSC 7840, Bethesda, MD 20892, (301) 451-3848, [ainszte@csr.nih.gov](mailto:ainszte@csr.nih.gov).

*Name of Committee:* Musculoskeletal, Oral and Skin Sciences Integrated Review Group, Skeletal Biology Structures and Regeneration Study Section.

*Date:* October 25–26, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* Mehrdad M. Tondravi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892, (301) 435-1173, [tondravm@csr.nih.gov](mailto:tondravm@csr.nih.gov).

*Name of Committee:* Infectious Diseases and Microbiology Integrated Review Group, Prokaryotic Cell and Molecular Biology Study Section.

*Date:* October 26–27, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* St. Gregory Hotel, 2003 M Street, NW., Washington, DC 20036.

*Contact Person:* Diane L. Stassi, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892, (301) 435-2514, [stassid@csr.nih.gov](mailto:stassid@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Physiology and Pathobiology of the Organ Systems.

*Date:* October 26–27, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Courtyard by Marriott, 1600 Rhode Island Avenue, Washington, DC 20036.

*Contact Person:* Peter J. Perrin, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 2183, MSC 7818, Bethesda, MD 20892, (301) 435-0682, [perrinp@csr.nih.gov](mailto:perrinp@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, SBMI 11: Small Business Imaging: Optical and Video.

*Date:* October 26, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

*Contact Person:* Robert J. Nordstrom, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5118, MSC 7854, Bethesda, MD 20892, (301) 435-1175, [nordstr@csr.nih.gov](mailto:nordstr@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, SBMI 10: Small Business Medical Imaging: PET/MRI/X-ray.

*Date:* October 27, 2004.

*Time:* 8 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814.

*Contact Person:* Robert J. Nordstrom, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5118, MSC 7854, Bethesda, MD 20892, (301) 435-1175, [nordstr@csr.nih.gov](mailto:nordstr@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel, Cancer Immunopathology and Immunotherapy (CII).

*Date:* October 27–28, 2004.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Churchill Hotel, 1914 Connecticut Avenue, NW., Washington, DC 20009.

*Contact Person:* Marcia Litwack, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6206, MSC 7804, Bethesda, MD 20892, (301) 435-1719.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: September 17, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–21448 Filed 9–23–04; 8:45 am]

**BILLING CODE 4140-01-M**

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of partially exclusive licenses in (1) India; (2) China; and (3) Brazil to practice the invention embodied in U.S. Serial Number 60/094,425, filed July 28, 1998, PCT filed (PCT/US99/17036) on July 27, 1999, and National Stage filed in China, India, Korea, Australia, Canada, Europe, Japan, Brazil and the U.S., entitled “Multivalent Human-Bovine Rotavirus Vaccine” (DHHS ref. E-015–1998/0) as follows: (1) Co-exclusive licenses in India only to Biological E LTD, having a place of business in Hyderabad, India, and Bharat Biotech International LTD, having a place of business in Hyderabad, India; (2) non-exclusive licenses exclusively offered to companies and/or institutions within China; and (3) exclusive license in Brazil only to Fundacao Instituto Butantan, having a place of business in Sao Paulo, Brazil. The patent rights in these inventions have been assigned to the Government of the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 23, 2004 will be considered.

**ADDRESSES:** Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan Ano, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; E-mail: [anos@od.nih.gov](mailto:anos@od.nih.gov); Telephone: (301) 435–5515; Facsimile: (301) 402–0220.

**SUPPLEMENTARY INFORMATION:** The technology embodied in the above patent rights involves multivalent immunogenic compositions comprising at least four human-bovine reassortant rotaviruses, where the gene encoding VP7 protein from G1, G2, G3, or G4 human rotavirus strain is inserted into a bovine rotavirus backbone. These VP7 serotypes represent the clinically most important human rotavirus serotypes, which depends on VP4 and VP7 proteins, both found in the viral capsid and both of which independently induce neutralizing antibodies. Additionally, human-bovine reassortants for VP7 serotypes G5 and G9 and a bovine-bovine reassortant for VP7 G10 serotype are mentioned. Each of these reassortants is monovalent, and

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Partially-Exclusive Licenses: Human-Bovine Reassortant Rotavirus Vaccine

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

administered as a multivalent mixture. Compared to other human-bovine rotavirus reassortants, the compositions described in this technology induce an immunological response at significantly lower dosage than other human-bovine rotavirus reassortants (which required 10–100 times the dose of human-rhesus reassortants) and does not result in a low-grade, transient fever.

The prospective partially exclusive licenses will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective partially exclusive licenses may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to development of human-bovine reassortant rotavirus vaccines.

The licensed territory will be exclusive as outlined above and excluding U.S., Europe, and Canada.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: September 17, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04–21426 Filed 9–23–04; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Complementary and Alternative Medicine Announcement of Draft 5-Year Strategic Plan

**ACTION:** Notice.

**SUMMARY:** The National Center for Complementary and Alternative Medicine (NCCAM) is developing its 5-year strategic plan (2005–2009), and invites the public to provide comments on a draft of this plan. The draft plan will be publicly available through the NCCAM Web site at <http://nccam.nih.gov> from on or about October 4 through November 15, 2004. The

public is invited to provide comments through the mail and via the NCCAM Web site.

### Background

The National Center for Complementary and Alternative Medicine (NCCAM) was established in 1998 with the mission of exploring complementary and alternative healing practices in the context of rigorous science, training CAM researchers, and disseminating authoritative information to the public and professionals.

To date, NCCAM's efforts to rigorously study CAM, to train CAM researchers, to conduct outreach, and to facilitate integration have been guided by NCCAM's current strategic plan, "Expanding Horizons of Healthcare: Five Year Strategic Plan 2001–2005" located on the NCCAM Web site at <http://nccam.nih.gov/about/plans/fiveyear/index.htm>. Since its inception, NCCAM has funded over 800 research projects and has over 700 grantee publications.

NCCAM's new strategic plan will stipulate strategic goals and will outline a research agenda for CAM domains and scientific areas, based on identified needs and opportunities.

The public is invited to review the draft strategic plan and provide comments from October 4 through November 15, 2004. The draft plan may be viewed at <http://nccam.nih.gov/>. Hard copies of the plan may be obtained by calling 1–888–644–6226 or by e-mailing to [info@nccam.nih.gov](mailto:info@nccam.nih.gov).

### Request for Comments

The public is invited to provide comments on the draft strategic plan for 2005–2009. Comments may be provided through the NCCAM Web site at <http://nccam.nih.gov> or via U.S. mail to: Strategic Plan Feedback, National Center for Complementary and Alternative Medicine, NIH, 31 Center Drive, MSC 2182, Bethesda, MD 20892–2182.

**FOR FURTHER INFORMATION:** To request more information, visit the NCCAM Web site at <http://nccam.nih.gov>, call 1–888–644–6226, or e-mail [info@nccam.nih.gov](mailto:info@nccam.nih.gov).

### Comments Due Date

Comments regarding the draft of NCCAM's strategic plan are best assured of having their full effect if received by November 15, 2004.

Dated: September 15, 2004.

**Christy Thomsen,**

*Director, Office of Communications and Public Liaison, National Center for Complementary and Alternative Medicine, National Institutes of Health.*

[FR Doc. 04–21427 Filed 9–23–04; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[USCG–2004–19167]

#### Statutory Monetary Civil Penalty Increase for Bridge Violations

**AGENCY:** Coast Guard, DHS.

**ACTION:** Notice.

**SUMMARY:** This notice is to inform the public that on August 9, 2004, President Bush signed the Coast Guard and Maritime Transportation Act of 2004 which, in part, increases the monetary civil penalty amount the Coast Guard can levy for a violation of bridge regulations and statutes.

**FOR FURTHER INFORMATION CONTACT:** If you have questions on this notice, call Chris Jaufmann, Coast Guard, telephone 202–267–0368.

**SUPPLEMENTARY INFORMATION:** 33 U.S.C. 495(b), 499(c), 502(c), and 533(b), authorizes assessing penalties for violations of bridge regulations found in 33 CFR parts 115, 116, 117, and 118. The maximum penalty amount that could be levied per bridge violation per day was \$1,000. In 1997, the maximum penalty amount was raised to \$1,100 to adjust for inflation.

On August 9, 2004 President Bush signed the Coast Guard and Maritime Transportation Act of 2004 into law. (Pub. L. 108–293) section 601 of this act, raises the maximum civil penalty amount that the Coast Guard can levy per bridge violation per day from \$1,100 to \$5000 for the remainder of 2004. The Act then raises that amount by \$5000 increments at the start of each calendar year until 2008 when the maximum amount allowed per violation per day will be \$25,000. Thus, the penalty is \$5,000 for a violation occurring in 2004; \$10,000 for a violation occurring in 2005; \$15,000 for a violation occurring in 2006; \$20,000 for a violation occurring in 2007; and \$25,000 for a violation occurring in 2008 and every year after that. This increase took effect immediately upon signature.